Abstract
Blood pressure is a major determinant of cardiovascular risk. Blood pressure target to reach with antihypertensive therapy, and the population to whom it should apply, remain debatted. Blood pressure goals established by scientific societies may be revised after the publication of the US multicenter SPRINT study results (Systolic Blood Pressure Intervention Trial) obtained in 2015. Analysis of the generalizability of the SPRINT results shows that they may not be directly applied to the french population which is at lower risk than the US population and would have major medical and economic implications.
© 2016 médecine/sciences – Inserm.
MeSH terms
-
Aged
-
Angiotensin II Type 2 Receptor Blockers / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antihypertensive Agents / adverse effects
-
Antihypertensive Agents / therapeutic use*
-
Aspirin / therapeutic use
-
Blood Pressure*
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / prevention & control
-
Diabetic Angiopathies
-
Diabetic Cardiomyopathies
-
France
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Middle Aged
-
Multicenter Studies as Topic
-
National Institutes of Health (U.S.)
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Treatment Outcome*
-
United States
Substances
-
Angiotensin II Type 2 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Aspirin